Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.46 |
| ▸ | AKT1 | P31749 | 7/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.45 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.45 |
| ▸ | ILK | Q13418 | 3/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589604 | 0.86 | ALOX5 (0.50) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4677441 | 0.82 | AKT1 (0.65) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16855789 | 0.78 | AKT1 (0.64) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16589596 | 0.77 | ALOX5 (0.53) | ALOX5AKT1PTGESPPARGPPARA | |
| SCHEMBL1286217 | 0.77 | AKT1 (0.53) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16583014 | 0.75 | AKT1 (0.48) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16583013 | 0.75 | AKT1 (0.48) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL1286032 | 0.71 | AKT1 (0.45) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL9301858 | 0.70 | ALOX5 (0.49) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL16589773 | 0.70 | ALOX5 (0.66) | ALOX5PTGESPPARGPPARANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158106-A1 | TOCOPHEROL DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158106-A1 | TOCOPHEROL DERIVATIVES AND METHODS OF USE | TTPA, OSBP, PCTP | ALOX5 229/4885AKT1 3496/4885PDPK1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.